Pulmovant, a clinical-stage biotechnology company and Roivant company, will present results from the Phase 2 PHocus study of mosliciguat in pulmonary hypertension associated with interstitial lung disease, or PH-ILD, at the European Respiratory Society International Congress 2026. The presentation is scheduled for 12:15 p.m. CEST, or 6:15 a.m. ET, on Sept. 8 and will be delivered by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension. The global, randomized, double-blind, placebo-controlled study enrolled 135 adults. Mosliciguat is a potential first-in-class, once-daily inhaled soluble guanylate cyclase activator designed to provide targeted pulmonary vasodilation with limited systemic side effects. It is also being evaluated with inhaled treprostinil in the open-label Phase 2 PHactor study. PH-ILD is a form of Group 3 pulmonary hypertension associated with progressive lung disease, and up to 200,000 patients across the United States and Europe are living with the condition, which has limited or no approved treatment options.